Spirometry to Motivate Quit-Smoking Attempts: Message Development and Testing
Spirometry to Motivate Quit-Smoking Attempts: Message Development and Testing
批准号:
7315919
负责人:
David A Kaminsky
金额:
$7.55万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-15 至 2010-07-31
关键词:
AffectAgeAreaBehavior TherapyBehavioralCancer ControlCancer EtiologyCardiovascular systemCessation of lifeCharacteristicsClinicalClinical Practice GuidelineDataDependenceDeveloped CountriesDevelopmentDiseaseEffectivenessFutureGuidelinesInternational Agency for Research on CancerInterventionInterviewKnowledgeLaboratoriesLanguageLettersLogisticsLungMalignant NeoplasmsMeasurementMeasuresMotivationNicotine DependenceNumbersPatientsPersonsPhysiciansPrimary Health CarePublished CommentPulmonary function testsRandomized Clinical TrialsRandomized Controlled TrialsRateRecording of previous eventsRegression AnalysisReportingResearchRespiratory physiologyRiskRoleSmokeSmokerSmokingSpirometryStandards of Weights and MeasuresStructureTelephoneTestingTimeTobacco smokeTobacco useUnited States Agency for Healthcare Research and QualityUnited States Dept. of Health and Human ServicesUniversity Hospitalsbasecigarette smokingcommunication theorydesigneffectiveness clinical trialfollow-upimprovedmortalitypulmonary functionrespiratorysexsmoking cessationtool
中文摘要
描述(由申请人提供):吸烟是工业化国家可预防疾病的主要原因,特别是心血管和呼吸系统疾病以及癌症。2000年,美国卫生与公众服务部发布了一份以证据为基础的《治疗烟草使用和依赖临床实践指南》,其中指出,吸烟但不愿戒烟的患者应接受干预,以增加他们戒烟的动机。列出的动机之一是强调吸烟的风险。其中一种风险是肺活量测定法测量的肺功能下降。然而,肺活量测定法促进戒烟的证据是有限的。卫生保健研究和质量机构(AHRQ)最近得出结论,现有证据不支持在初级保健环境中使用肺活量测定法来提高戒烟率。然而,由于认识到这一工具的潜在重要性,AHRQ将随机对照试验的必要性列为未来研究的优先事项,以确定肺活量测定法在戒烟中的作用。在进行此类对照试验之前,我们需要了解为什么肺活量测定法尚未被证明能令人信服地促进戒烟。我们认为,肺活量测定在这方面失败的主要原因是,在戒烟重要性的背景下,测量的意义没有有效地传达给吸烟的患者。为了验证这一假设,我们设计了这一建议,以开发一种增强的[肺活量测定干预,包括激励信息和后续信件],然后测试这种[干预]对戒烟尝试率的影响。我们假设,通过增强的[肺活量测量干预]向当前吸烟者提供肺功能知识,与通过标准[干预]提供这些结果相比,将增加戒烟尝试率。我们的3个具体目标是:1)利用行为和沟通理论的原理开发一个关于肺活量测定的增强动机信息;2)确定通过增强[肺活量测定干预]向当前吸烟者提供肺活量测定结果对戒烟企图率的影响;3)确定哪些临床特征与戒烟尝试有关,并确定肺活量测定法提高戒烟尝试率的有效性的障碍。这些数据将为今后开展肺活量测定法对戒烟有效性的大型临床试验提供框架。吸烟是世界上导致癌症相关死亡的主要原因。因此,戒烟是控制癌症最重要的行为干预。这个项目将决定是否测量吸烟者的肺功能,并将结果传递给他们,使用一个强大的激励策略,将增加他们试图戒烟的可能性。如果是这样,那么这种策略可以用于大规模的研究,以确定肺功能的结果是否能有效地让人们戒烟。
英文摘要
DESCRIPTION (provided by applicant): Smoking is a leading cause of preventable disease in industrialized countries, especially cardiovascular and respiratory illness, and cancer. In 2000, the US Department of Health and Human Services issued an evidenced-based Clinical Practice Guideline on Treating Tobacco Use and Dependence that states that patients who smoke, but are unwilling to quit, should receive an intervention that increases their motivation to quit. Among the motivations listed is highlighting the risks of cigarette smoking. One of these risks is decreased lung function as measured by spirometry. However, the evidence that spirometry enhances smoking cessation is limited. The Agency for Healthcare Research and Quality (AHRQ) recently concluded that the available evidence does not support the use of spirometry in the primary care setting in order to improve smoking cessation rates. Nonetheless, in recognition of the potential importance of this tool, the AHRQ lists the need for randomized controlled trials to determine the role of spirometry in smoking cessation as a priority of future research. Before such controlled trials can take place, we need to understand why spirometry has not been shown to convincingly enhance smoking cessation. We believe that the primary reason spirometry has failed in this regard is because the meaning of the measurement in the context of the importance of smoking cessation is not effectively communicated to the patient who smokes. To test this hypothesis, we have designed this proposal to develop an enhanced [spirometry intervention, to include a motivational message and follow-up letter], and then test the impact of this [intevention] on the quit attempt rate. We hypothesize that providing knowledge of lung function to current smokers through an enhanced [spirometry intervention] will increase the quit attempt rate compared to delivery of these results through a standard [intervention]. Our 3 Specific Aims are: 1) To develop an enhanced motivational message about spirometry using principles of behavioral and communication theory; 2) To determine the effect of delivering spirometry results to current smokers through an enhanced [spirometry intervention] on the quit attempt rate; 3) To determine which clinical characteristics are associated with quit attempts, and identify barriers to the effectiveness of spirometry in enhancing the quit attempt rate. These data will provide the framework for developing a future large clinical trial of the effectiveness of spirometry on smoking cessation. Cigarette smoking is the leading cause cancer-related death in the world. Therefore, quitting smoking is the most important behavioral intervention in cancer control. This project will determine whether measuring lung function in smokers and delivering the results to them using a strong motivational strategy will increase the likelihood that they will try to stop smoking. If so, then this strategy can be used in a large scale study to determine whether lung function results are effective in getting people to quit smoking.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Efficacy of Pranayama in COPD
-
批准号:8465268
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2012
-
负责人:David A Kaminsky
-
依托单位:
The Efficacy of Pranayama in COPD
-
批准号:8282238
-
项目类别:
-
资助金额:$21.4万
-
财政年份:2012
-
负责人:David A Kaminsky
-
依托单位:
Spirometry to Motivate Quit-Smoking Attempts: Message Development and Testing
-
批准号:7484223
-
项目类别:
-
资助金额:$3.76万
-
财政年份:2007
-
负责人:David A Kaminsky
-
依托单位:
Spirometry to Motivate Quit-Smoking Attempts: Message Development and Testing
-
批准号:7665036
-
项目类别:
-
资助金额:$3.76万
-
财政年份:2007
-
负责人:David A Kaminsky
-
依托单位:
COBRE: UVT: AIRWAY PARENCHYMAL MECHANICAL DYSFUNCTION
-
批准号:7170235
-
项目类别:
-
资助金额:$27.34万
-
财政年份:2005
-
负责人:David A Kaminsky
-
依托单位:
Biomechanics of the Lung Periphery in Asthma
-
批准号:7041547
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2004
-
负责人:David A Kaminsky
-
依托单位:
COBRE: UVT: AIRWAY PARENCHYMAL MECHANICAL DYSFUNCT IN ASTHMA: PULMONARY, STEROID
-
批准号:7011652
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2004
-
负责人:David A Kaminsky
-
依托单位:
HYPERPNEA AND PARENCHYMAL PATHOPHYSIOLOGY IN ASTHMA
-
批准号:2771169
-
项目类别:
-
资助金额:$9.05万
-
财政年份:1995
-
负责人:David A Kaminsky
-
依托单位:
HYPERPNEA AND PARENCHYMAL PATHOPHYSIOLOGY IN ASTHMA
-
批准号:6056082
-
项目类别:
-
资助金额:$12.37万
-
财政年份:1995
-
负责人:David A Kaminsky
-
依托单位:
HYPERPNEA AND PARENCHYMAL PATHOPHYSIOLOGY IN ASTHMA
-
批准号:2211776
-
项目类别:
-
资助金额:$9.05万
-
财政年份:1995
-
负责人:David A Kaminsky
-
依托单位:
HYPERPNEA AND PARENCHYMAL PATHOPHYSIOLOGY IN ASTHMA
-
批准号:2211777
-
项目类别:
-
资助金额:$9.05万
-
财政年份:1995
-
负责人:David A Kaminsky
-
依托单位:
HYPERPNEA AND PARENCHYMAL PATHOPHYSIOLOGY IN ASTHMA
-
批准号:2519211
-
项目类别:
-
资助金额:$9.05万
-
财政年份:1995
-
负责人:David A Kaminsky
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: